News

Newsletter

UN removes Cannabis from List of Narcotic Substances

On December 2, 2020, through its Commission on Narcotics, the United Nations approved a recommendation issued by WHO – World Health Organization through its Committee of Experts on Drug Addiction and removed Cannabis from Schedule 4 of its Single Narcotic Convention (1961, amended in 1972). Schedule 4 contains the substances considered as the most dangerous to human health and whose possible therapeutic benefits do not outweigh their risks – reason why they should be considered outlawed. Among the substances in Schedule 4 is, for example, heroin.
With the approval of WHO recommendation 5.1, P&D with Cannabis is now easier. It should be noted, however, that Cannabis remains on Schedule 1 of the same Convention (the same where several opioids are, such as fentanyl), being subject to the following controls:
• Limitation of use for medical and scientific purposes of all phases of the substance's trade (manufacturing, domestic and international trade);
• Government authorization requirement for the domestic market and specific authorization (import and export authorization) for each individual international transaction;
• Obligation of all participants in the trade to keep detailed records of their transactions with the substance;
• Requirement of a medical prescription to supply or dispense medications to individuals;
• Submission to a system to limit the quantities of medicines available, by manufacture or import or both, in each country and territory, for those necessary for medical and scientific purposes.
WHO had also recommended the downgrading of THC, Dronabinol and their isomers to Schedule 1, as well as the removal of CBD from the scope of the Convention and the inclusion of preparations in which it is predominant in Schedule 3 of the Convention (less restrictive). However, these other recommendations were not approved.
The approval of Recommendation 5.1 has the potential to modify Anvisa's position on research with cannabinoids, both for marketing purposes and with regard to previous consent of patent applications.
For more information, do not hesitate to contact our team via email: regulatorio@kasznarleonardos.com.
*This newsletter is only a general update on the subject and should not be considered as legal advice.
 
Back

Last related news

March 6, 2023

Brazilian Data Protection Authority approves the Regulation on Dosimetry and Application of Administrative Penalties

The Brazilian Data Protection Authority (“ANPD” or “Authority”) published, on February 28th, 2023, the Regulation on Dosimetry and Application of Administrative Penalties Brazilian Data Protection Authority approves the Regulation on Dosimetry and Application of Administrative Penalties

Ler notícia

January 17, 2023

The Future Legal Regulation Of Artificial Intelligence In Brazil

Several Bills are being debated in the Brazilian National Congress with the objective of regulating the development and use of artificial intelligence The Future Legal Regulation Of Artificial Intelligence In Brazil

Ler notícia

January 9, 2023

New flexibility on the remittance of royalty payments abroad

In the last days of December 2022, new regulations entered into force easing up the remittance of royalty payments abroad. However, local New flexibility on the remittance of royalty payments abroad

Ler notícia